Metformin in endometrial cancer from metabolic regulation to precision therapeutics
Abstract
Endometrial cancer (EC) is the most common gynecologic malignancy in developed countries, with incidence rising in parallel with obesity, insulin resistance, and type 2 diabetes (T2DM). EC exhibits characteristic metabolic vulnerabilities, including hyperactive glycolysis, mitochondrial dysfunction, and PI3K/AKT/mTOR pathway activation, driven by unopposed estrogen stimulation and systemic metabolic dysregulation. Metformin, a first-line antidiabetic agent and mitochondrial complex I inhibitor, has emerged as a promising repurposed drug for EC prevention and treatment through dual mechanisms: direct tumor suppression via AMPK/mTOR, PI3K/Akt, Wnt/β-catenin, and endoplasmic reticulum stress pathways; and indirect metabolic microenvironment improvement via insulin sensitization, sex hormone-binding globulin upregulation, and immune microenvironment remodeling. This narrative review comprehensively summarizes available preclinical mechanistic insights and published clinical evidence across EC disease spectrum: chemoprevention in high-risk populations (obesity, PCOS), fertility-preserving treatment for early-stage disease, and combination strategies for advanced/recurrent EC. We synthesize existing data rather than adopting formal systematic review methodology with predefined database retrieval and PRISMA-compliant screening criteria. We critically analyze survival outcomes, response heterogeneity contingent upon diabetic status and molecular subtypes, and current bottlenecks in…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.